NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

The insiders at NVCR obviously know their company is over valued. No secret there. But NWBO’s lack of progress is not only offering them a longer runway to sell and capitalize at a higher share price, but also for insiders to receive additional bonus options, and I assume get past the vesting periods.

NVCR and their investors have made huge money with not much to show for it in terms of what they offer patients. I would say insiders at NVCR are laughing in the back of their limos on their long weekend drives to their homes in the Hamptons or the Vineyard — while I whistle my happy tunes on my park bench.